Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Rossi

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Plos Neglected Tropical Diseases|September 26, 2025
Comparing diagnostic methods for historical arbovirus outbreaks: Insights from 19th century "dengue" epidemicsTimothee Bonifay, Mathieu Nacher, Clémence Bonnefoy, et al.
Journal for Immunotherapy of Cancer|March 31, 2025
Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killingSophie Guia, Aurore Fenis, Camille Baudesson De Chanville, et al.
The American Journal of Medicine|October 25, 2017
Effect of a Red Blood Cell Transfusion on Biological Markers Used to Determine the Cause of Anemia: A Prospective StudyAntoine Froissart, Benjamin Rossi, Brigitte Ranque, et al.
Nature Biotechnology|January 12, 2023
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123Laurent Gauthier, Angela Virone-Oddos, Jochen Beninga, et al.
Cell|June 4, 2019
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor ImmunityLaurent Gauthier, Ariane Morel, Nadia Anceriz, et al.
Cell Reports|May 23, 2019
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer TherapiesIvan Perrot, Henri-Alexandre Michaud, Marc Giraudon-Paoli, et al.
Open Research Europe|August 30, 2023
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor controlMathieu Bléry, Manel Mrabet-Kraiem, Ariane Morel, et al.
Cell Reports. Medicine|February 19, 2026
Targeting BCMA in multiple myeloma with a trifunctional NK cell engagerAlexandre Tang, Laurent Gauthier, Elisa Zaghi, et al.
Cell|December 4, 2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsPascale André, Caroline Denis, Caroline Soulas, et al.
Science Immunology|November 15, 2024
A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphomaOlivier Demaria, Guillaume Habif, Marie Vetizou, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Plos Neglected Tropical Diseases|September 26, 2025
Comparing diagnostic methods for historical arbovirus outbreaks: Insights from 19th century "dengue" epidemicsTimothee Bonifay, Mathieu Nacher, Clémence Bonnefoy, et al.
Journal for Immunotherapy of Cancer|March 31, 2025
Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killingSophie Guia, Aurore Fenis, Camille Baudesson De Chanville, et al.
The American Journal of Medicine|October 25, 2017
Effect of a Red Blood Cell Transfusion on Biological Markers Used to Determine the Cause of Anemia: A Prospective StudyAntoine Froissart, Benjamin Rossi, Brigitte Ranque, et al.
Nature Biotechnology|January 12, 2023
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123Laurent Gauthier, Angela Virone-Oddos, Jochen Beninga, et al.
Cell|June 4, 2019
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor ImmunityLaurent Gauthier, Ariane Morel, Nadia Anceriz, et al.
Cell Reports|May 23, 2019
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer TherapiesIvan Perrot, Henri-Alexandre Michaud, Marc Giraudon-Paoli, et al.
Open Research Europe|August 30, 2023
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor controlMathieu Bléry, Manel Mrabet-Kraiem, Ariane Morel, et al.
Cell Reports. Medicine|February 19, 2026
Targeting BCMA in multiple myeloma with a trifunctional NK cell engagerAlexandre Tang, Laurent Gauthier, Elisa Zaghi, et al.
Cell|December 4, 2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsPascale André, Caroline Denis, Caroline Soulas, et al.
Science Immunology|November 15, 2024
A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphomaOlivier Demaria, Guillaume Habif, Marie Vetizou, et al.
Pageof 5